Abstract
Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME).
Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME.
Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group.
Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.
Keywords: Diabetic macular edema, diabetic retinopathy, fluorescein angiography, fundus autofluorescence, microperimetry, laser treatment, optical coherence tomography, subthreshold micropulse laser, retinal safety.
Current Medicinal Chemistry
Title:Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues
Volume: 20 Issue: 26
Author(s): Stela Vujosevic, Ferdinando Martini, Enrica Convento, Evelyn Longhin, Olympia Kotsafti, Raffaele Parrozzani and Edoardo Midena
Affiliation:
Keywords: Diabetic macular edema, diabetic retinopathy, fluorescein angiography, fundus autofluorescence, microperimetry, laser treatment, optical coherence tomography, subthreshold micropulse laser, retinal safety.
Abstract: Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME).
Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME.
Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group.
Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.
Export Options
About this article
Cite this article as:
Vujosevic Stela, Martini Ferdinando, Convento Enrica, Longhin Evelyn, Kotsafti Olympia, Parrozzani Raffaele and Midena Edoardo, Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues, Current Medicinal Chemistry 2013; 20 (26) . https://dx.doi.org/10.2174/09298673113209990030
DOI https://dx.doi.org/10.2174/09298673113209990030 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina
Current Alzheimer Research Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Models for the Study of Angiogenesis
Current Pharmaceutical Design Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Current Pharmaceutical Design A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story
Current Neuropharmacology Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications
Current Medicinal Chemistry Safety and Efficacy of Dexamethasone Intravitreal Implant (Ozurdex) for the Treatment of Persistent Macular Edema Secondary to Retinal Vein Occlusion in Eyes Previously Treated with Anti-Vascular Endothelial Growth Factors
Current Drug Safety The Production of Solid Dosage Forms from Non-Degradable Polymers
Current Pharmaceutical Design Intraocular Immune Mechanisms in Uveitis
Current Immunology Reviews (Discontinued) Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets PEDF in Angiogenic Eye Diseases
Current Molecular Medicine Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase
Current Pharmaceutical Design